Nu Med Plus Stock Probability of Future OTC Stock Price Finishing Over 0.0163
Nu-Med Plus' future price is the expected price of Nu-Med Plus instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Nu Med Plus performance during a given time horizon utilizing its historical volatility. Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in population.
Please specify Nu-Med Plus' target price for which you would like Nu-Med Plus odds to be computed.
Nu-Med |
Nu-Med Plus Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Nu-Med Plus for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Nu Med Plus can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Nu Med Plus has some characteristics of a very speculative penny stock | |
| Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu-Med Plus until it has trouble settling it off, either with new capital or with free cash flow. So, Nu-Med Plus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nu-Med to invest in growth at high rates of return. When we think about Nu-Med Plus' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (830.06 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nu Med Plus currently holds about 2.54 K in cash with (206.83 K) of positive cash flow from operations. | |
| Roughly 62.0% of Nu-Med Plus outstanding shares are owned by corporate insiders |
Nu-Med Plus Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Nu-Med OTC Stock often depends not only on the future outlook of the current and potential Nu-Med Plus' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Nu-Med Plus' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 79.3 M | |
| Shares Float | 27.7 M |
Nu-Med Plus Technical Analysis
Nu-Med Plus' future price can be derived by breaking down and analyzing its technical indicators over time. Nu-Med OTC Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Nu Med Plus. In general, you should focus on analyzing Nu-Med OTC Stock price patterns and their correlations with different microeconomic environments and drivers.
Nu-Med Plus Predictive Forecast Models
Nu-Med Plus' time-series forecasting models is one of many Nu-Med Plus' otc stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Nu-Med Plus' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the otc stock market movement and maximize returns from investment trading.
Things to note about Nu Med Plus
Checking the ongoing alerts about Nu-Med Plus for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Nu Med Plus help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Nu Med Plus generated a negative expected return over the last 90 days | |
| Nu Med Plus has high historical volatility and very poor performance | |
| Nu Med Plus has some characteristics of a very speculative penny stock | |
| Nu Med Plus currently holds 2.06 K in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Nu Med Plus has a current ratio of 0.03, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nu-Med Plus until it has trouble settling it off, either with new capital or with free cash flow. So, Nu-Med Plus' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nu Med Plus sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nu-Med to invest in growth at high rates of return. When we think about Nu-Med Plus' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (830.06 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nu Med Plus currently holds about 2.54 K in cash with (206.83 K) of positive cash flow from operations. | |
| Roughly 62.0% of Nu-Med Plus outstanding shares are owned by corporate insiders |
Other Information on Investing in Nu-Med OTC Stock
Nu-Med Plus financial ratios help investors to determine whether Nu-Med OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nu-Med with respect to the benefits of owning Nu-Med Plus security.